All In Biotech

Drug Trial Radar · NCT05957978

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

A Randomized, Open-label, Phase II, Single-centre Study to Evaluate the Efficacy, Safety and Pharmacokinetics of LXE408 in Patients With Primary Visceral Leishmaniasis in Ethiopia

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Mar 29, 2024

Primary completion

Jun 27, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 44 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and \<45 years) patients with confirmed primary visceral leishmaniasis in Ethiopia.

Conditions

  • Primary Visceral Leishmaniasis

Interventions

  • LXE408Drug

    Film-coated tablets

  • sodium stibogluconateDrug

    Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.

  • ParomomycinDrug

    Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients treated with LXE408 with initial cure at Day 28Time frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Gondar

    Gonder, Ethiopia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.